Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing istradefylline and application thereof

A technology of istradefylline and its composition, which is applied in the field of pharmaceutical compositions and pharmaceutical compositions containing istradefylline, can solve the problems of large side effects and high treatment costs, and achieve the goals of reducing side effects, improving conditions, and reducing treatment costs Effect

Active Publication Date: 2015-08-05
NANJING ANGGU PHARMA TECH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the shortcomings of existing neurodegenerative disease therapeutic drugs in clinical application, especially the defects of large side effects and high treatment cost in Parkinson's therapeutic drugs, the present invention provides a drug for the treatment of Parkinson's with definite therapeutic effect and less side effects. pharmaceutical composition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing istradefylline and application thereof
  • Pharmaceutical composition containing istradefylline and application thereof
  • Pharmaceutical composition containing istradefylline and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 istradefylline puerarin sustained-release tablet

[0026]

[0027]Preparation process: Weigh the prescribed amount of istradefylline, puerarin, starch, sodium alginate and low-substituted hydroxypropyl cellulose and mix evenly. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

Embodiment 2

[0028] Embodiment 2 istradefylline puerarin tablet

[0029]

[0030] Preparation process: Weigh the prescribed amount of istradefylline, puerarin, starch, dextrin and low-substituted hydroxypropyl cellulose and mix evenly. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

Embodiment 3

[0031] Embodiment 3 istradefylline puerarin capsules

[0032]

[0033] Preparation process: pass the main drug and auxiliary materials in the prescription through a 100-mesh sieve, weigh istradefylline, puerarin, microcrystalline cellulose, lactose, and micropowder silica gel, mix them evenly, and fill capsules to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition and application thereof, specifically to a pharmaceutical composition containing istradefylline and application thereof, belonging to the field of medicine. To overcome disadvantages of conventional neurodegenerative disease therapeutics in neurodegenerative disease therapeutics, especially the defects of great side effect and high treatment cost of therapeutics for the Parkinson disease, the invention provides the pharmaceutical composition containing istradefylline. When the pharmaceutical composition containing istradefylline is applied to treatment of the Parkinson disease, side-effects of drugs in treatment of the Parkinson disease are substantially reduced, treatment cost for the Parkinson disease is lowered down at the same time, and a breakthrough is made to the golden rule that levodopa has to be used in clinical treatment of the Parkinson disease; thus, the pharmaceutical composition containing istradefylline has good medical application prospects.

Description

technical field [0001] The invention relates to a pharmaceutical composition and its application, in particular to a pharmaceutical composition containing istradefylline and its application, and belongs to the field of medicine. Background technique [0002] Parkinson's disease, also known as parkinsonism, is the most common degenerative disease of the central nervous system in middle-aged and elderly people. Tremor refers to the trembling and shaking of the head and limbs, and paralysis refers to the inability of a part or all of the limbs to move voluntarily, including movement disorders, tremors, and muscle stiffness. As my country gradually enters into an aging population society, its incidence rate has been increasing year by year in recent years, and the incidence rate gradually increases with age. The age of onset generally begins at the age of 50-65, the incidence rate at the age of 60 is about 1‰, and the incidence rate at the age of 70 reaches 3‰-5‰. There are abo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/522A61P25/28A61P25/16A61K31/352
Inventor 程浩
Owner NANJING ANGGU PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com